	US 11,891,453 B2
	Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
Gal Markel, Tel Aviv (IL); Tehila Ben Moshe, Misgav (IL); Yair Sapir, Burgata (IL); Ilana Mandel, Kiryat Yam (IL); Jacob Schachter, Givatayim (IL); and Rona Ortenberg, Tel Aviv (IL)
Assigned to FAMEWAVE LTD., Rehovot (IL)
Filed by Famewave Ltd., Rehovot (IL)
Filed on Sep. 29, 2020, as Appl. No. 17/037,136.
Application 17/037,136 is a continuation of application No. 15/683,087, filed on Aug. 22, 2017, abandoned.
Application 15/683,087 is a continuation of application No. 14/350,970, granted, now 9,771,431, issued on Sep. 26, 2017, previously published as PCT/IL2012/050402, filed on Oct. 10, 2012.
Claims priority of application No. PCT/IL2011/000808 (WO), filed on Oct. 11, 2011.
Prior Publication US 2021/0070884 A1, Mar. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/42 (2006.01); C07K 16/30 (2006.01); A61K 35/17 (2015.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/42 (2013.01) [A61K 35/17 (2013.01); A61K 39/39566 (2013.01); A61K 45/06 (2013.01); C07K 16/3007 (2013.01); G01N 33/686 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

20 Claims

1. A chimeric monoclonal antibody or an antibody fragment thereof which recognizes human CEACAM1 comprising (i) a heavy chain variable domain sequence having a sequence set forth in SEQ ID NO: 26; (ii) a light chain variable domain sequence having a sequence set forth in SEQ ID NO: 28; and (iii) a set of CDR sequences selected from: a set of SEQ ID NOs: 13, 14, 15, 16, 17, and 18; and a set of SEQ ID NOs: 7, 8, 9, 10, 11, and 12.